Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies

Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies

Plain Language Summary This study looked at alemtuzumab, an approved treatment for multiple sclerosis (MS). People who receive alemtuzumab may develop thyroid problems. The researchers wanted to know whether people who developed thyroid problems with alemtuzumab had a worse quality of life compared...

Full description

Bibliographic Details
Main Authors: Antonio Bertolotto, Rafael Arroyo, Elisabeth G. Celius, Giancarlo Comi, Eva Kubala Havrdova, William David Honeycutt, Samuel F. Hunter, Guillermo Izquierdo, Barbara Kornek, Tamara Miller, Dimos D. Mitsikostas, Barry A. Singer, Tjalf Ziemssen, Luke Chung, Nadia Daizadeh, Salman Afsar, Lobat Hashemi, Peter Senior
Format: Article
Language:English
Published: Adis, Springer Healthcare 2020-05-01
Series:Neurology and Therapy
Subjects:
Alemtuzumab
Health-related quality of life
Thyroid adverse events
Relapsing-remitting multiple sclerosis
Online Access:https://doi.org/10.1007/s40120-020-00191-7

Internet

https://doi.org/10.1007/s40120-020-00191-7

Similar Items